- Home
- GNFT vs SCPH Comparison
GNFT vs SCPH Comparison
Compare GNFT & SCPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNFT
- SCPH
- Stock Information
- Founded
- GNFT 1999
- SCPH 2013
- Country
- GNFT France
- SCPH United States
- Employees
- GNFT N/A
- SCPH N/A
- Industry
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- SCPH Biotechnology: Pharmaceutical Preparations
- Sector
- GNFT Health Care
- SCPH Health Care
- Exchange
- GNFT Nasdaq
- SCPH Nasdaq
- Market Cap
- GNFT 186.3M
- SCPH 299.0M
- IPO Year
- GNFT 2019
- SCPH 2017
- Fundamental
- Price
- GNFT $4.25
- SCPH $5.63
- Analyst Decision
- GNFT Strong Buy
- SCPH Buy
- Analyst Count
- GNFT 2
- SCPH 3
- Target Price
- GNFT $11.00
- SCPH $12.00
- AVG Volume (30 Days)
- GNFT 2.8K
- SCPH 2.3M
- Earning Date
- GNFT 09-22-2025
- SCPH 11-12-2025
- Dividend Yield
- GNFT N/A
- SCPH N/A
- EPS Growth
- GNFT N/A
- SCPH N/A
- EPS
- GNFT 0.03
- SCPH N/A
- Revenue
- GNFT $73,187,701.00
- SCPH $49,969,000.00
- Revenue This Year
- GNFT $5.15
- SCPH $108.95
- Revenue Next Year
- GNFT N/A
- SCPH $78.30
- P/E Ratio
- GNFT $134.73
- SCPH N/A
- Revenue Growth
- GNFT 105.01
- SCPH 107.79
- 52 Week Low
- GNFT $2.55
- SCPH $1.94
- 52 Week High
- GNFT $6.42
- SCPH $6.28
- Technical
- Relative Strength Index (RSI)
- GNFT 56.17
- SCPH 64.37
- Support Level
- GNFT $3.91
- SCPH $4.33
- Resistance Level
- GNFT $4.27
- SCPH $5.62
- Average True Range (ATR)
- GNFT 0.13
- SCPH 0.05
- MACD
- GNFT 0.01
- SCPH 0.01
- Stochastic Oscillator
- GNFT 81.47
- SCPH 93.75
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs. The company's main product is Furoscix to treat congestion in patients with heart failure and edema in patients with chronic kidney disease. Furoscix is a novel formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self-administered subcutaneously via a single-use, disposable, and wearable on-body delivery system.